## Osteosarcoma with Pulmonary Metastases ### Clinical Context This case describes osteosarcoma of the proximal tibia (second most common site after distal femur) in an adolescent with elevated tumor markers. The question focuses on **metastatic disease detection and prognostic significance**. **Key Point:** Pulmonary metastases are present in 15–20% of osteosarcoma patients at initial diagnosis and develop in up to 80% during the disease course. The presence and extent of pulmonary metastases is the single most important prognostic factor after achieving local control. ### Why Pulmonary Metastases? Osteosarcoma spreads via **hematogenous route** (not lymphatic), with a predilection for the lungs because: 1. Tumor cells enter venous circulation from the primary site 2. Lungs are the first capillary bed encountered 3. Pulmonary nodules are the most common distant metastases (80% of metastatic disease) **High-Yield:** Bilateral pulmonary nodules indicate advanced metastatic disease. Patients with pulmonary metastases at diagnosis have a worse prognosis, but aggressive surgical resection of pulmonary nodules (thoracotomy or VATS) combined with chemotherapy can still achieve long-term survival in selected cases. ### Metastatic Patterns in Osteosarcoma | Site | Frequency | Clinical Significance | |------|-----------|----------------------| | **Lungs (bilateral nodules)** | 80% of metastases | Most common; resectable in some cases | | **Lungs (unilateral)** | Common at diagnosis | Better prognosis than bilateral | | **Bone (skip lesions)** | 5–10% | Indicates advanced disease | | **Lymph nodes** | Rare (<5%) | Unusual for osteosarcoma | | **Liver/brain** | <5% | Late manifestation | **Clinical Pearl:** Bilateral pulmonary nodules in osteosarcoma are metastatic disease, not primary lung pathology. Each nodule represents a separate tumor deposit and requires aggressive treatment (chemotherapy + surgical resection if feasible). ### Staging and Prognosis **Mnemonic: OSTEOSARCOMA STAGING = Osteosarcoma Spreads Through Extraosseous Osteoid; Outcome depends on Staging, Aggressive chemotherapy response, Resectability of metastases, Chemotherapy sensitivity, Osteoid production rate, Metastatic burden, Age (younger = better)** 1. **Localized disease** (no metastases): 5-year survival ~70% with multimodal therapy 2. **Pulmonary metastases at diagnosis**: 5-year survival ~40–50% (if resectable) 3. **Unresectable metastases or poor chemotherapy response**: 5-year survival <20% ### Prognostic Factors (in order of importance) 1. **Presence and extent of metastases** — bilateral pulmonary nodules = worse prognosis 2. **Chemotherapy response** — good histologic necrosis (>90%) = better outcome 3. **Resectability of primary and metastases** — complete resection improves survival 4. **Tumor size and location** — large tumors and axial skeleton = worse 5. **Alkaline phosphatase/LDH elevation** — prognostic markers but less important than metastatic status **High-Yield:** The most important prognostic factor is whether pulmonary metastases are present and whether they are resectable. Patients with resectable pulmonary metastases who undergo chemotherapy + primary resection + pulmonary metastasectomy have significantly better outcomes than those with unresectable disease. ### Management of Pulmonary Metastases 1. **Chemotherapy** — neoadjuvant to primary tumor and metastases 2. **Primary tumor resection** — limb-sparing surgery preferred 3. **Pulmonary metastasectomy** — VATS or thoracotomy if resectable (can be repeated) 4. **Adjuvant chemotherapy** — continuation after surgery [cite:Robbins 10e Ch 27; Orthopaedic Surgery Board Review] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.